Neurocrine Biosciences announced two-year Phase 3 data from the CAHtalyst Pediatric study showing that CRENESSITY (crinecerfont) treatment slows bone age progression and improves predicted adult height in children with classic congenital adrenal hyperplasia (CAH). Patients with advanced bone age at baseline experienced stabilization or improvement in bone age and an average increase of 4.7 cm in predicted adult height. Caregiver surveys reported high satisfaction and optimism about treatment outcomes. CRENESSITY also enabled reduced glucocorticoid doses, potentially lowering long-term side effects. These findings highlight CRENESSITY's potential to improve growth and quality of life in pediatric CAH patients.
VYKAT XR (diazoxide choline) treatment demonstrated significant and lasting improvements in hyperphagia and behavioral symptoms in individuals with Prader-Willi syndrome (PWS) for up to three years. Participants who resumed VYKAT XR after a 16-week w...
Neurocrine Biosciences reported that CRENESSITY (crinecerfont) significantly improved hormone levels and reduced glucocorticoid doses in patients with classic congenital adrenal hyperplasia (CAH) due to 11β-hydroxylase deficiency, a rare form of CAH....
Neurocrine Biosciences announced that two-year data from their Phase 3 CAHtalyst Adult study shows CRENESSITY (crinecerfont) improves cardiometabolic outcomes like insulin resistance, body weight, and bone health in adults with classic congenital adr...
